Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Retail Industry News NEXE Innovations makes bold U.S. entry through EKOCUPS partnership NEXE Innovations Inc. has expanded its reach into the United States by partnering with EKOCUPS, a renowned online… byPallavi MadhirajuNovember 29, 2024